Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Sunao Tanaka"'
Autor:
Kosuke Kawaguchi, Yurina Maeshima, Hiroshi Ishiguro, Kazuhiko Yamagami, Sachiko Takahara, Hirofumi Suwa, Masae Torii, Shigenori Nagai, Yasuaki Sagara, Wakako Tsuji, Hiroyasu Yamashiro, Takeshi Kotake, Shinji Fukuda, Kuniaki Saito, Yasuko Yamamoto, Masako Kataoka, Yuki Himoto, Atsushi Yonezawa, Yukiko Fukui, Yuki Nakamura, Wei Li, Sunao Tanaka, Satoshi Morita, Masakazu Toi
Publikováno v:
Cancer Research. 83:P2-26
Background: Abemaciclib is a selective CDK4 and CDK6 inhibitor with demonstrated efficacy in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The most common adverse event across previous trials was
Autor:
Yukiko Fukui, Kosuke Kawaguchi, Ryuji Murakami, Wei Li, Yuki Nakamura, Yurina Maeshima, Sunao Tanaka, Shinpei Kawaoka, Eiji Suzuki, Masakazu Toi
Publikováno v:
Cancer Research. 83:P3-08
Background: Stable humanized immune mice transplanted with peripheral blood mononuclear cells (PBMCs) derived from breast cancer patients are important models for assessing the tumor immune responses and the tumor immune microenvironment in breast ca
Autor:
Sunao Tanaka, Masakazu Toi, Souichi Adachi, Natsuki Wariishi, Nobuko Kawaguchi-Sakita, Yasuhiko Kamikubo
Publikováno v:
Cancer Research. 80:P3-06
In breast cancer, both incidence and mortality have been increasing. Triple negative breast cancer (TNBC), one of breast cancer subtypes, is a heterogeneous nature that is negative for estrogen receptor (ER), progesterone receptor (PR) and human epit
Autor:
Sunao Tanaka, Eiji Suzuki, Takeshi Kotake, Shinpei Kawaoka, Kosuke Kawaguchi, Tomomi Nishimura, Fengling Pu, Masakazu Toi
Publikováno v:
Cancer Research. 82:6161-6161
Background: HER3 signal pathways in cancer cells are thought to be involved in up-regulation of PD-L1 expression, resulting in “cold” tumor immune microenvironment (TIME). However, little is known on the association of HER3 expression and immune
Autor:
Nayuko Sato, Katsumasa Kuroi, Y Teramura, Shintaro Takao, M. Toi, Sunao Tanaka, Tomomi Fujisawa, Shinji Ohno, Yutaka Yamamoto, H. Iwata, Hiroko Bando, Takayuki Kadoya, Hiroshi Ishiguro
Publikováno v:
Cancer Research. 76:P1-16
Background The association between CYP2D6 polymorphisms and efficacy of tamoxifen (TAM) is inconclusive, partly due to inaccurate prediction of active metabolite, endoxifen exposure by solely CYP2D6 genotype. Moreover, TAM dose escalation is not effe
Autor:
Fengling Pu, Fumiaki Sato, Sunao Tanaka, Junji Itou, Natsue Uehiro, Shigehira Saji, Masakazu Toi
Publikováno v:
Cancer Research. 75:P1-06
Backgrounds: Breast cancer (BC) is a heterogeneous disease and usually divided into 5 subtypes according to clinicopathologic features. These subtypes have concordance with mRNA-based subtypes called as "intrinsic subtypes". Further gene expression a
Publikováno v:
Cancer Research. 79:2862-2862
Background and objective: Bevacizumab is an antibody of VEGF and suppresses tumor angiogenesis. It exhibited therapeutic efficacy for metastatic breast cancer, but impact on overall survival has not been proved. VEGF is a multi-function molecule. We
Publikováno v:
Cancer Research. 79:P5-03
Breast cancer is the most common cancer in women in the world. Among breast cancer subtypes, triple-negative breast cancer is aggressive. Because there is no effective therapy for triple-negative breast cancer, development of a novel therapeutic stra
Autor:
Masakazu Toi, Fumiaki Sato, Sunao Tanaka, Junji Itou, Noriko Senda, A Sehara-Fujisawa, A Iida
Publikováno v:
Cancer Research. 79:P2-01
Metastasis inhibition may improve survival of breast cancer patients. Our previous study revealed that a transcription factor SALL4 promotes cell migration for metastasis through up-regulation of integrin α6β1 in metastatic basal-like breast cancer
Autor:
Takayuki Kadoya, Sunao Tanaka, Shoichiro Ohtani, Nobuki Matsunami, Noriyuki Masuda, Makiko Mizutani, Nayuko Sato, Yasuhiro Yanagita, Shinji Ohno, Yutaka Yamamoto, M. Toi, Takashi Morimoto, Satoshi Morita, Tomomi Fujisawa, Kenji Higaki, K Kaneko, Mina Takahashi, Toshimi Takano
Publikováno v:
Cancer Research. 73:P3-14
Background: We compared and evaluated three 6-cycle, docetaxel and cyclophosphamide (TC)-containing chemotherapy regimens in a multicenter randomized phase II study. The main aim was to investigate whether anthracyclines are needed or can be omitted,